Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
btgplc.com

See what CB Insights has to offer

Investments

12

Portfolio Exits

3

Partners & Customers

10

Service Providers

1

About BTG International

BTG is medical device development and healthcare service provider. It provides Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care and licensing business. It operates through three segments: Interventional Medicine, Pharmaceuticals and Licensing.

BTG International Headquarter Location

5 Fleet Place

London, England, EC4M 7RD,

United Kingdom

+44 (0)20 7575 0000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BTG International

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find BTG International in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Research containing BTG International

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BTG International in 1 CB Insights research brief, most recently on Aug 21, 2019.

Latest BTG International News

BTG plc

Aug 9, 2020

NewsnReleases   August 9, 2020 BTG plc is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. BTG was a constituent of the FTSE 250 Index until it was acquired by Boston Scientific in August 2019. BTG earns revenues from specialty pharmaceutical and interventional medicine product sales and on royalties from partnered products. It trades as BTG International Inc. in the United States and as BTG International Ltd. in the United Kingdom. Type:                     Public

BTG International Investments

12 Investments

BTG International has made 12 investments. Their latest investment was in New Radiomedicine as part of their Series B on July 7, 2019.

CBI Logo

BTG International Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/17/2019

Series B

New Radiomedicine

$16.86M

Yes

8

11/13/2018

Corporate Minority

Veran Medical Technologies

$20M

Yes

3

11/24/2010

Series D

Xention

$12.6M

No

1

7/19/2005

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/31/2004

Series A

Subscribe to see more

Subscribe to see more

10

Date

7/17/2019

11/13/2018

11/24/2010

7/19/2005

8/31/2004

Round

Series B

Corporate Minority

Series D

Series B

Series A

Company

New Radiomedicine

Veran Medical Technologies

Xention

Subscribe to see more

Subscribe to see more

Amount

$16.86M

$20M

$12.6M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

3

1

10

10

BTG International Portfolio Exits

3 Portfolio Exits

BTG International has 3 portfolio exits. Their latest portfolio exit was Veran Medical Technologies on December 04, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/4/2020

Acquired

$99M

5

2/29/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

11/30/1995

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/4/2020

2/29/2008

11/30/1995

Exit

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

0

10

BTG International Acquisitions

8 Acquisitions

BTG International acquired 8 companies. Their latest acquisition was Novate Medical on September 07, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/7/2018

Series C

$99M

$17.15M

Acquired

3

9/7/2018

Subscribe to see more

$99M

Subscribe to see more

10

10/5/2017

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

4/24/2017

Subscribe to see more

$99M

Subscribe to see more

10

5/6/2016

Growth Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

9/7/2018

9/7/2018

10/5/2017

4/24/2017

5/6/2016

Investment Stage

Series C

Series C

Growth Equity

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$17.15M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

BTG International Partners & Customers

10 Partners and customers

BTG International has 10 strategic partners and customers. BTG International recently partnered with Carrick Therapeutics on October 10, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

10/11/2018

Licensee

Ireland

DUBLIN, Ireland, 11 October 2018. Carrick Therapeutics in-licenses targeted ovarian cancer treatment from BTG and appoints George Golumbeski as Chairman - Carrick Therapeutics

Carrick Therapeutics , a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines , has today announced that it has licensed exclusive worldwide rights to develop and commercialise BTG945 , now CT900 , an investigational targeted ovarian cancer drug , from the global specialist healthcare company BTG plc .

2

6/21/2018

Partner

United States

Bothell, WA, 21 June 2018. PERT Consortium and BTG Form Strategic Partnership

In their new partnership , BTG and the PERT Consortium ™ are uniting to address this disease via expanding options for professional education , expanding clinical research , establishing quality benchmarks for care of PE , and developing new mobile technologies to convene PERT teams and improve decision-making .

1

5/31/2018

Partner

United States

BTG and OMNY Partner to Improve Treatment of Snake Bite Victims.

BTG International Inc. , the global healthcare company , is partnering with OMNY to improve visibility of inventory data for its antivenom product CroFab ® using distributed ledger technology .

1

9/27/2017

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

5/19/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/11/2018

6/21/2018

5/31/2018

9/27/2017

5/19/2017

Type

Licensee

Partner

Partner

Partner

Partner

Business Partner

Country

Ireland

United States

United States

United Kingdom

United States

News Snippet

DUBLIN, Ireland, 11 October 2018. Carrick Therapeutics in-licenses targeted ovarian cancer treatment from BTG and appoints George Golumbeski as Chairman - Carrick Therapeutics

Carrick Therapeutics , a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines , has today announced that it has licensed exclusive worldwide rights to develop and commercialise BTG945 , now CT900 , an investigational targeted ovarian cancer drug , from the global specialist healthcare company BTG plc .

Bothell, WA, 21 June 2018. PERT Consortium and BTG Form Strategic Partnership

In their new partnership , BTG and the PERT Consortium ™ are uniting to address this disease via expanding options for professional education , expanding clinical research , establishing quality benchmarks for care of PE , and developing new mobile technologies to convene PERT teams and improve decision-making .

BTG and OMNY Partner to Improve Treatment of Snake Bite Victims.

BTG International Inc. , the global healthcare company , is partnering with OMNY to improve visibility of inventory data for its antivenom product CroFab ® using distributed ledger technology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

BTG International Service Providers

1 Service Provider

BTG International has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

BTG International Team

5 Team Members

BTG International has 5 team members, including current Chief Executive Officer, Louise Makin.

Name

Work History

Title

Status

Louise Makin

Chief Executive Officer

Current

Ian Harvey

Chief Executive Officer

Former

Christine Soden

Chief Financial Officer

Former

Matthew Gantz

Executive Vice President

Former

Nermeen Varawalla

Senior Vice President

Former

Name

Louise Makin

Ian Harvey

Christine Soden

Matthew Gantz

Nermeen Varawalla

Work History

Title

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Executive Vice President

Senior Vice President

Status

Current

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.